Whether and how coffee use influences glucose metabolism is still a matter for debate. We investigated whether baseline coffee consumption is longitudinally associated with risk of impaired fasting glucose in a cohort of 18-to-45 year old subjects screened for stage 1 hypertension and whether CYP1A2 polymorphism modulates this association. A total of 1,180 nondiabetic patients attending 17 hospital centers were included. Seventy-four percent of our subjects drank coffee. Among the coffee drinkers, 87 % drank 1–3 cups/day (moderate drinkers), and 13 % drank over 3 cups/day (heavy drinkers). Genotyping of CYP1A2 SNP was performed by real time PCR in 639 subjects. At the end of a median follow-up of 6.1 years, impaired fasting glucose was found in 24.0 % of the subjects. In a multivariable Cox regression coffee use was a predictor of impaired fasting glucose at study end, with a hazard ratio (HR) of 1.3 (95 % CI 0.97–1.8) in moderate coffee drinkers and of 2.3 (1.5–3.5) in heavy drinkers compared to abstainers. Among the subjects stratified by CYP1A2 genotype, heavy coffee drinkers carriers of the slow *1F allele (59 %) had a higher adjusted risk of impaired fasting glucose (HR 2.8, 95 % CI 1.3–5.9) compared to abstainers whereas this association was of borderline statistical significance among the homozygous for the A allele (HR 1.7, 95 % CI 0.8–3.8). These data show that coffee consumption increases the risk of impaired fasting glucose in hypertension particularly among carriers of the slow CYP1A2 *1F allele.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Fox CS, Coady S, Sorlie PD, D’Agostino RB Sr, Pencina MJ, Vasan RS, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation. 2007;115:1544–50.
Tuomilehto J, Eriksson J. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.
Huxley R, Lee CM, Barzi F, Timmermeister L, Czernichow S, Perkovic V, et al. Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch Intern Med. 2009;169:2053–63.
Jiang X, Zhang D, Jiang W. Coffee and caffeine intake and incidence of type 2 diabetes mellitus: a meta-analysis of prospective studies. Eur J Nutr. 2014;53:25–38.
van Dam RM, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ. Coffee consumption and incidence of impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes: the Hoorn Study. Diabetologia. 2004;47:2152–9.
Agardh EE, Carlsson S, Ahlbom A, Efendic S, Grill V, Hammar N, et al. Coffee consumption, type 2 diabetes and impaired glucose tolerance in Swedish men and women. J Intern Med. 2004;255:645–52.
Yamaji T, Mizoue T, Tabata S, Ogawa S, Yamaguchi K, Shimizu E, et al. Coffee consumption and glucose tolerance status in middle-aged Japanese men. Diabetologia. 2004;47:2145–51.
Rebello SA, Chen CH, Naidoo N, Xu W, Lee J, Chia KS, et al. Coffee and tea consumption in relation to inflammation and basal glucose metabolism in a multi-ethnic Asian population: a cross-sectional study. Nutr J. 2011;10:61–70.
Moisey LL, Kacker S, Bickerton AC, Robinson LE, Graham TE. Caffeinated coffee consumption impairs blood glucose homeostasis in response to high and low glycemic index meals in healthy men. Am J Clin Nutr. 2008;87:1254–61.
van Dam RM, Pasman WJ, Verhoef P. Effects of coffee consumption on fasting blood glucose and insulin concentrations: randomized controlled trials in healthy volunteers. Diabetes Care. 2004;27:2990–2.
Gavrieli A, Fragopoulou E, Mantzoros CS, Yannakoulia M. Gender and body mass index modify the effect of increasing amounts of caffeinated coffee on postprandial glucose and insulin concentrations; a randomized, controlled, clinical trial. Metabolism. 2013;62:1099–106.
American Diabetes Association. Executive summary: standards of medical care in diabetes—2012. Diabetes Care. 2012;35(Suppl 1):S4–10.
Sartori M, Semplicini A, Siffert W, Mormino P, Mazzer A, Pegoraro F, et al. G-protein beta3-subunit gene 825T allele and hypertension: a longitudinal study in young grade I hypertensives. Hypertension. 2003;42:909–14.
Palatini P, Dorigatti F, Santonastaso M, Cozzio S, Biasion T, Garavelli G, et al. Association between coffee consumption and risk of hypertension. Ann Med. 2007;39:545–53.
Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA. 2006;295:1135–41.
Palatini P, Ceolotto G, Ragazzo F, Dorigatti F, Saladini F, Papparella I, et al. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens. 2009;27:1594–601.
Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med. 2004;164:2126–34.
Casiglia E, Paleari CD, Petucco S, Bongiovì S, Colangeli G, Baccilieri MS, et al. Haemodynamic effects of coffee and purified caffeine in normal volunteers: a placebo-controlled clinical study. J Hum Hypertens. 1992;6:95–9.
Palatini P, Canali C, Graniero GR, Rossi GP, De Toni R, Santonastaso M, et al. Relationship of plasma renin activity with caffeine intake and physical training in mild hypertensive men. Eur J Epidemiol. 1996;12:485–91.
Winnicki M, Bonso E, Dorigatti F, Longo D, Zaetta V, Mattarei M, et al. Effect of body weight loss on blood pressure after 6 years of follow-up in stage 1 hypertension. Am J Hypertens. 2006;19:1103–9.
Palatini P, Penzo M, Canali C, Pessina AC. Validation of the A&D TM-2420 model 7 for ambulatory blood pressure monitoring and effect of microphone replacement on its performance. J Ambul Monit. 1991;4:281–8.
O’Brien E, Mee F, Atkins N. O’ Malley K. Accuracy of the Spacelabs 90207 determined by the British Hypertension Society protocol. J Hypertens. 1991;9:573–5.
National Center for Biotechnology Information. dbSNP Home Page. http://www.ncbi.nlm.nih.gov/SNP/index.html. Accessibility verified on Feb 04, 2014.
Keijzers GB, De Galan BE, Tack CJ, Smits P. Caffeine can decrease insulin sensitivity in humans. Diabetes Care. 2002;25:364–9.
Thong FS, Derave W, Kiens B, Graham TE, Ursø B, Wojtaszewski JF, et al. Caffeine-induced impairment of insulin action but not insulin signaling in human skeletal muscle is reduced by exercise. Diabetes. 2002;51:583–90.
Pizziol A, Tikhonoff V, Paleari CD, Russo E, Mazza A, Ginocchio G, et al. Effects of caffeine on glucose tolerance: a placebo controlled study. Eur J Clin Nutr. 1998;52:846–9.
Mougios V, Ring S, Petridou A, Nikolaidis MG. Duration of coffee- and exercise-induced changes in the fatty acid profile of human serum. J Appl Physiol. 2003;94:476–84.
Lane JD, Barkauskas CE, Surwit RS, Feinglos MN. Caffeine impairs glucose metabolism in type 2 diabetes. Diabetes Care. 2004;27:2047–8.
Battram DS, Arthur R, Weekes A, Graham TE. The glucose intolerance induced by caffeinated coffee ingestion is less pronounced than that due to alkaloid caffeine in men. J Nutr. 2006;136:1276–80.
Moisey LL, Robinson LE, Graham TE. Consumption of caffeinated coffee and a high carbohydrate meal affectspostprandial metabolism of a subsequent oral glucose tolerance test in young, healthy males. Br J Nutr. 2010;103:833–41.
Bonita JS, Mandarano M, Shuta D, Vinson J. Coffee and cardiovascular disease: in vitro, cellular, animal, and human studies. Pharmacol Res. 2007;55:187–98.
Johnston KL, Clifford MN, Morgan LM. Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. Am J Clin Nutr. 2003;78:728–33.
Shearer J, Farah A, de Paulis T, Bracy DP, Pencek RR, Graham TE, et al. Quinides of roasted coffee enhance insulin action in conscious rats. J Nutr. 2003;133:3529–32.
Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics. 1992;2:73–7.
Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C to A polymorphism in intron 1 of the cytochrome P450 1A2 (CYP1A2) gene tested with caffeine. Br J Clin Pharmacol. 1999;47:445–9.
Han XM, Ou-Yang DS, Lu PX, Jiang CH, Shu Y, Chen XP, et al. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734 polymorphisms of human CYP1A2. Pharmacogenetics. 2001;11:429–35.
Avogaro A, Toffolo G, Valerio A, Cobelli C. Epinephrine exerts opposite effects on peripheral glucose disposal and glucose-stimulated insulin secretion: a stable label intravenous glucose tolerance test minimal model study. Diabetes. 1996;45:1373–8.
Thong FS, Graham TE. Caffeine-induced impairment of glucose tolerance is abolished by beta-adrenergic receptor blockade in humans. J Appl Physiol. 2002;92:2347–52.
Fredholm BB. Astra Award Lecture: adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol. 1995;76:93–101.
Green MS, Symons MJA. Comparison of the logistic risk function and the proportional hazards model in prospective epidemiologic studies. J Chronic Dis. 1983;36:715–24.
Peduzzi P, Holford T, Detre K, Chan YK. Comparison of the logistic and Cox regression models when outcome is determined in all patients after a fixed period of time. J Chronic Dis. 1987;40:761–7.
Annesi I, Moreau T, Lellouch J. Efficiency of the logistic regression and Cox proportional hazards models in longitudinal studies. Stat Med. 1989;8:1515–21.
van Dam RM, Feskens EJ. Coffee consumption and risk of type 2 diabetes mellitus. Lancet. 2002;9344:1477–8.
van Dam RM, Willett WC, Manson JE, Hu FB. Coffee, caffeine, and risk of type 2 diabetes: a prospective cohort study in younger and middle-aged US women. Diabetes Care. 2006;2:398–403.
Hjellvik V, Tverdal A, Strom H. Boiled coffee intake and subsequent risk for type 2 diabetes. Epidemiology. 2011;3:418–21.
Sartorelli DS, Fagherazzi G, Balkau B, Touillaud MS, Boutron-Ruault MC, de Lauzon-Guillain B, et al. Differential effects of coffee on the risk of type 2 diabetes according to meal consumption in a French cohort of women: the E3N/EPIC cohort study. Am J Clin Nutr. 2010;4:1002–12.
The study was funded by the University of Padova, Padova, Italy, and by the Associazione “18 Maggio 1370”, San Daniele del Friuli, Italy.
Conflict of interest
The authors have no financial interest in the subject matter or materials discussed in the manuscript.
About this article
Cite this article
Palatini, P., Benetti, E., Mos, L. et al. Association of coffee consumption and CYP1A2 polymorphism with risk of impaired fasting glucose in hypertensive patients. Eur J Epidemiol 30, 209–217 (2015). https://doi.org/10.1007/s10654-015-9990-z